Yale Medicine

Nanoparticles, Genome Therapy & Antibodies - The Zhou Research Lab at Yale School of Medicine

The Zhou Research Lab at Yale School of Medicine is a biomedical‑engineering group that builds platform technologies for delivering therapeutics to the brain. Its work spans three distinct avenues: engineered nanoparticles for crossing the blood‑brain barrier, a novel “step‑engineering” approach that delivers gelatinous gene‑therapy vectors for neuro‑genetic disorders, and a new class of cell‑penetrating antibodies aimed at diseases such as Parkinson’s and Huntington’s. The lab emphasizes technology over biology, leveraging established biological methods while innovating on delivery mechanisms. Nanoparticles are being optimized for brain‑cancer and stroke applications, step‑engineering is positioned as the only global effort targeting gelatinous gene therapy, and antibody engineering seeks intracellular access to treat neurodegenerative conditions. All three platforms are slated for clinical translation, with nanoparticle trials expected within two years and antibody candidates moving toward near‑term clinical use. Collaboration is central to the lab’s strategy. Partnerships with physicians—such as Dr. *** for oncology, Professor James Hansen for antibody work, and Kevin *** for stroke research—provide the clinical insight needed to move discoveries from bench to bedside. The team explicitly avoids reinventing biological assays, focusing instead on engineering breakthroughs that can be rapidly deployed in clinical settings. If successful, these technologies could reshape treatment paradigms for a range of neurological diseases, offering targeted delivery that overcomes the brain’s protective barriers. The lab’s translational focus promises to accelerate the pipeline from academic research to FDA‑approved therapies, potentially delivering new options for patients with limited current treatments.